Federal Advocacy / Issues / Legislation

Join in the effort to promote the Federal Patient Access to Pharmacist's Services.  Take action

Community pharmacy advocacy
and issues at the national level with NCPA.  Read more 

Health-system pharmacy advocacy
and issues at the federal level with  Find out more.

Click here for contact information to Montana's Congressional Delegation
Email, phone, fax and mailing address for US Representative Ryan Zinke, Senator Steve Daines and Senator Jon Tester.

NCPA’s Advocacy Report provides a weekly detailed summary of recent and breaking legislative, regulatory and state developments impacting independent community pharmacy, and NCPA efforts to effect policies to benefit its membership and the industry. The weekly report is distributed to NCPA leadership, key committees, allied organizations / stakeholders and major contributors to the NCPA LDF and PAC. 

Week Ending March 11, 2017
Bill Recognizing Pharmacists as Health Care Providers Continues to Gain Momentum:  S. 109/H.R. 592, the Pharmacy and Medically Underserved Areas Enhancement Act continues to gain sponsors. The bill recognizes pharmacists as health care providers and permits state-licensed pharmacists in medically underserved communities to both provide and be reimbursed for an expanded scope of patient-care services under the Medicare Part B program.  Read all articles in the report.

Week Ending March 4, 2017
Generic Drug Payment Bill Introduced in the U.S. House of Representatives:  Bipartisan legislation to increase transparency in generic drug payments in taxpayer-funded federal health programs and preserve patient access to local community pharmacies was introduced in the House this week by Reps. Doug Collins (R-Ga.) and Dave Loebsack (D-Iowa) along with six of their colleagues.  H.R. 1316, the Prescription Drug Price Transparency Act...  Read the full report.  
Related articles -- Generic Drug Pricing Transparency and Statement for the Record.  

Week Ending February 25, 2017
NCPA Hosts DIR Stakeholder Call:  This week NCPA hosted a call with industry partners providing an update on recent developments regarding NCPA’s efforts on pharmacy DIR fees.  Click here for highlights of the briefing and the full report.

Week Ending February 18, 2017
House/Senate DIR Bills Introduced: This week, Reps. Morgan Griffith (R-Va.) and Peter Welch (D-Vt.), along with 16 of their colleagues, introduced H.R. 1038, the "Improving Transparency and Accuracy in Medicare Part D Drug Spending Act," that would prohibit retroactive pharmacy DIR fees.  The bill was introduced with very strong support ...Read the full report.

Week Ending February 11, 2017
NCPA Responds to PBM Efforts to Limit Potential Reforms:  An apparently leaked memorandum has surfaced from Mark Merritt, president and CEO of the Pharmaceutical Care Management Association (PCMA), to the association's board of directors. It outlines PCMA's strategies to mitigate possible reforms of PBMs. NCPA responded to news surrounding the leaked memo by stressing the untold profits PBMs have extracted from patients, drug manufacturers and health plans, with very little oversight and almost no transparency. Read the full report.

Week Ending February 4, 2017
Sen. Brown Submits DIR Fees Question as part of Senate Finance Committee Confirmation Hearing for HHS Nominee:  Rep. Tom Price (R-Ga.), President Trump's nominee to lead the Department of Health and Human Services (HHS) testified last week before the Senate Finance Committee.  At NCPA’s request, independent pharmacy champion Sen. Sherrod Brown (D-OH) submitted a question on DIR fees and pending CMS guidance for the record and Rep. Price has subsequently provided an answer. Read the full report.